


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): An aqueous composition comprising a thiazole derivative of the formula (I):




wherein

R^1 is acyl;

X is a bivalent residue derived from optionally substituted thiazole;

Y is a bond, lower alkylene, lower alkenylene or $-CONH-$; and

Z is a group of the formula:



wherein R^2 is a group of the formula: -A-B-D-E


wherein A is a bond, lower alkylene, -NH- or $-SO_2-$;

B is a bond, lower alkylene, -CO- or -O-;

D is a bond, lower alkylene, -NH- or $-CH_2NH-$, provided that when B is -CO- or

-O-, D is not a bond; and

E is optionally protected amino, -N=CH₂,



Preliminary Amendment
National Stage Entry of PCT/JP05/005607


wherein

Q is -S- or -NH-; and


R³ is hydrogen, lower alkyl, lower alkylthio or
-NH-R⁴ wherein R⁴ is hydrogen, -NH₂ or
lower alkyl;

or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alcohol, boric acid or its salt, and water.

2. (original): The composition of claim 1, wherein Z of the formula (I) is a group of the formula:




wherein R² is a group of the formula:



(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen, -NH₂ or lower alkyl); -NH₂; -CH₂NH₂; -CH₂ONH₂;


-CH₂ON=CH₂;




or a pharmaceutically acceptable salt thereof.

Preliminary Amendment
National Stage Entry of PCT/JP05/005607

3. (original): The composition of claim 2, wherein R² of the formula (I) is a group of the formula:



(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen or lower alkyl);
-CH₂NH₂; -CH₂ONH₂; -CH₂ON=CH₂;



or a pharmaceutically acceptable salt thereof.

4. (currently amended): The composition of ~~any of claims 1 to 3~~ claim 1, wherein R¹ of the formula (I) is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

5. (currently amended): The composition of claim 1, wherein the thiazole thiazole derivative is

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

or

N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide,

Preliminary Amendment
National Stage Entry of PCT/JP05/005607

or a pharmaceutically acceptable salt thereof.

6. (new): The composition of claim 2, wherein R¹ of the formula (I) is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

7. (new): The composition of claim 3, wherein R¹ of the formula (I) is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.